The tumor accumulation of nanomedicines relies on the enhanced permeability and
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Abstract Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and
generally well tolerated when administered as a single agent to treat advanced breast …

Breast cancer is the most frequently diagnosed cancer and the principal cause of mortality
by malignancy in women and represents a main problem for public health worldwide. Tumor …

HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …

Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb)
family plays a crucial part in the development and evolution of cancer. Inhibiting the …

Simple Summary Trastuzumab is a humanized antibody that has significantly improved the
management and treatment outcomes of patients with cancers that overexpress HER2 …

Gastric cancer is the second leading cause of cancer mortality in the world and its
management, especially in advanced stages, has evolved relatively little. In particular, no …

HER2 amplification is seen in up to 20% of breast cancers and is associated with an
aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant …

Trastuzumab is a monoclonal antibody targeted against the human epidermal growth factor
receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of …